Description
Amgen’s Hidden Growth Engine: Why 17 Blockbuster Drugs Could Change Its Future!
Amgen Inc.’s third quarter financial results for 2026 reflect continued revenue growth and operational execution across a broad portfolio of products and pipeline candidates. Total revenues increased 8% year-over-year to $10.4 billion, driven by strong sales from six key growth drivers that collectively rose 27% year-over-year and accounted for over 70% of product sales. Seventeen products achieved double-digit sales growth, with an equivalent number now annualizing over $1 billion each. Notable performers included Repatha, which grew 37% to $1.1 billion amidst increased new-to-brand prescriptions and updated clinical guidelines, and EVENITY, which posted a 39% rise to $751 million supported by expanded physician adoption. TEZSPIRE in inflammatory disorders saw 43% growth to $538 million, outperforming market trends, while the rare disease portfolio expanded 21% to $1.6 billion, powered notably by UPLIZNA’s 191% surge to $451 million.



